Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 77

1.

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.

Shaw AT, Solomon BJ, Chiari R, Riely GJ, Besse B, Soo RA, Kao S, Lin CC, Bauer TM, Clancy JS, Thurm H, Martini JF, Peltz G, Abbattista A, Li S, Ou SI.

Lancet Oncol. 2019 Dec;20(12):1691-1701. doi: 10.1016/S1470-2045(19)30655-2. Epub 2019 Oct 25.

PMID:
31669155
2.

Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer.

Pavlakis N, Cooper C, John T, Kao S, Klebe S, Lee CK, Leong T, Millward M, O'Byrne K, Russell PA, Solomon B, Cooper WA, Fox S.

Pathology. 2019 Dec;51(7):673-680. doi: 10.1016/j.pathol.2019.08.006. Epub 2019 Oct 24.

PMID:
31668406
3.

Transcriptional suppression of the miR-15/16 family by c-Myc in malignant pleural mesothelioma.

Williams M, Cheng YY, Kirschner MB, Sarun KH, Schelch K, Winata P, McCaughan B, Kao S, Van Zandwijk N, Reid G.

Oncotarget. 2019 Jun 25;10(41):4125-4138. doi: 10.18632/oncotarget.27010. eCollection 2019 Jun 25.

4.

Rate of cancer progression as a predictive marker of efficacy of immunotherapy; an analysis in metastatic non-small-cell lung cancer.

Prasanna T, Arasaratnam M, Boyer M, McNeil C, Barnet MB, Asher R, Hui R, Nagrial A, Kao S.

Immunotherapy. 2019 Jun;11(8):657-665. doi: 10.2217/imt-2018-0180.

PMID:
31088240
5.

Salvage of renal transplant with vacuum-assisted thrombectomy of large iliocaval and allograft venous outflow thrombus.

Kao SD, Edwards MP, Kee ST, Moriarty JM.

Diagn Interv Radiol. 2019 May;25(3):238-241. doi: 10.5152/dir.2019.18232.

6.

A survey of patient and caregiver experience with malignant pleural mesothelioma.

Warby A, Dhillon HM, Kao S, Vardy JL.

Support Care Cancer. 2019 Dec;27(12):4675-4686. doi: 10.1007/s00520-019-04760-x. Epub 2019 Apr 3.

PMID:
30944991
7.

Patterns of care and survival of older patients with malignant pleural mesothelioma.

Linton A, Blinman P, Kao S, van Zandwijk N.

J Geriatr Oncol. 2019 Jul;10(4):573-576. doi: 10.1016/j.jgo.2019.02.013. Epub 2019 Mar 24.

PMID:
30917938
8.

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.

Shaw AT, Solomon BJ, Besse B, Bauer TM, Lin CC, Soo RA, Riely GJ, Ou SI, Clancy JS, Li S, Abbattista A, Thurm H, Satouchi M, Camidge DR, Kao S, Chiari R, Gadgeel SM, Felip E, Martini JF.

J Clin Oncol. 2019 Jun 1;37(16):1370-1379. doi: 10.1200/JCO.18.02236. Epub 2019 Mar 20.

PMID:
30892989
9.

High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes.

Ahmadzada T, Lee K, Clarke C, Cooper WA, Linton A, McCaughan B, Asher R, Clarke S, Reid G, Kao S.

Lung Cancer. 2019 Apr;130:35-41. doi: 10.1016/j.lungcan.2019.02.005. Epub 2019 Feb 7.

PMID:
30885349
10.

Patterns of care for stage III non-small cell lung cancer in Australia.

Parente P, Chan BA, Hughes BGM, Jasas K, Joshi R, Kao S, Hegi-Johnson F, Hui R, McLaughlin-Barrett S, Nordman I, Stone E.

Asia Pac J Clin Oncol. 2019 Jun;15(3):93-100. doi: 10.1111/ajco.13140. Epub 2019 Mar 14. Review.

PMID:
30868747
11.

Managing malignant pleural mesothelioma: experience and perceptions of health care professionals caring for people with mesothelioma.

Warby A, Dhillon HM, Kao S, Vardy JL.

Support Care Cancer. 2019 Sep;27(9):3509-3519. doi: 10.1007/s00520-019-4648-0. Epub 2019 Jan 25.

PMID:
30684047
12.

Treatment of erlotinib-induced acneiform eruption with chromophore gel-assisted phototherapy.

Mahendran A, Wong XL, Kao S, Sebaratnam DF.

Photodermatol Photoimmunol Photomed. 2019 May;35(3):190-192. doi: 10.1111/phpp.12446. Epub 2019 Jan 6. No abstract available.

13.

A supportive care intervention for people with metastatic melanoma being treated with immunotherapy: a pilot study assessing feasibility, perceived benefit, and acceptability.

Lacey J, Lomax AJ, McNeil C, Marthick M, Levy D, Kao S, Nielsen T, Dhillon HM.

Support Care Cancer. 2019 Apr;27(4):1497-1507. doi: 10.1007/s00520-018-4524-3. Epub 2018 Nov 3.

PMID:
30392112
14.

Prediction modelling using routine clinical parameters to stratify survival in Malignant Pleural Mesothelioma patients undergoing cytoreductive surgery.

Harris EJA, Kao S, McCaughan B, Nakano T, Kondo N, Hyland R, Nowak AK, de Klerk NH, Brims FJH.

J Thorac Oncol. 2019 Feb;14(2):288-293. doi: 10.1016/j.jtho.2018.10.005. Epub 2018 Oct 24.

PMID:
30366103
15.

Times to Diagnosis and Treatment of Lung Cancer in New South Wales, Australia: A Multicenter, Medicare Data Linkage Study.

Malalasekera A, Blinman PL, Dhillon HM, Stefanic NA, Grimison P, Jain A, D'Souza M, Kao SC, Vardy JL.

J Oncol Pract. 2018 Oct;14(10):e621-e630. doi: 10.1200/JOP.18.00125. Epub 2018 Sep 12.

PMID:
30207854
16.

Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy.

Levy D, Dhillon HM, Lomax A, Marthick M, McNeil C, Kao S, Lacey J.

Support Care Cancer. 2019 May;27(5):1845-1852. doi: 10.1007/s00520-018-4443-3. Epub 2018 Sep 4.

PMID:
30178142
17.

How long is too long? A scoping review of health system delays in lung cancer.

Malalasekera A, Nahm S, Blinman PL, Kao SC, Dhillon HM, Vardy JL.

Eur Respir Rev. 2018 Aug 29;27(149). pii: 180045. doi: 10.1183/16000617.0045-2018. Print 2018 Sep 30. Review.

18.

Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma.

Metaxas Y, Rivalland G, Mauti LA, Klingbiel D, Kao S, Schmid S, Nowak AK, Gautschi O, Bartnick T, Hughes BG, Bouchaab H, Rothschild SI, Pavlakis N, Wolleb S, Petrausch U, O'Byrne K, Froesch P, Löffler-Baumann M, Pratsch-Peter S, Russell P, Mingrone W, Savic S, Thapa B, Früh M, Pless M, von Moos R, John T.

J Thorac Oncol. 2018 Nov;13(11):1784-1791. doi: 10.1016/j.jtho.2018.08.007. Epub 2018 Aug 22.

19.

Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists.

Bui KT, Cooper WA, Kao S, Boyer M.

J Clin Med. 2018 Jul 31;7(8). pii: E192. doi: 10.3390/jcm7080192. Review.

20.

An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer.

Ahmadzada T, Kao S, Reid G, Boyer M, Mahar A, Cooper WA.

J Clin Med. 2018 Jun 15;7(6). pii: E153. doi: 10.3390/jcm7060153. Review.

Supplemental Content

Loading ...
Support Center